Valeant Pharmaceuticals International — Lazard Capital Markets Annual Life Sciences Conference 2005
10 slides from Valeant Pharmaceuticals International's conference presentation, Nov 30, 2005
Slide 1: Additional Disclosures to Support Presentations at Lazard Conference
EXHIBIT 99.2 November 30, 2005 Additional Disclosures to Support Presentations at Lazard Capital Markets Annual Life Sciences Conference During a presentation at the Lazard Capital Markets Annual Life Sciences Conference on November 30, 2005, Valeant Pharmaceuticals International (the “Company”) pre
Slide 2
Slide 3: Table 2: Adjusted Operating Income Reconciliation, 2003
Table 2 Valeant Pharmaceuticals International Reconciliation of Adjusted Operating Income and Financial Metrics Excluding Non-GAAP Adjustments to Operating Income and Financial Metrics, as measured under GAAP For the Year Ended December 31, 2003 (In millions) Non-GAAP GAAP Adjustments Adjusted Produ
Slide 4: Table 3: Adjusted Operating Income Reconciliation, 2002
Table 3 Valeant Pharmaceuticals International Reconciliation of Adjusted Operating Income and Financial Metrics Excluding Non-GAAP Adjustments to Operating Income and Financial Metrics, as measured under GAAP For the Year Ended December 31, 2002 (In millions) Non-GAAP GAAP Adjustments Adjusted Produ
Table 4 Valeant Pharmaceuticals International Reconciliation of Specialty Pharmaceuticals Adjusted Operating Income Excluding Non-GAAP Adjustments to Operating Income, as measured under GAAP For the Year Ended December 31, 2004 (In millions) Non-GAAP GAAP Adjustments Adjusted Specialty Pharmaceutica
Table 5 Valeant Pharmaceuticals International Reconciliation of Specialty Pharmaceuticals Adjusted Operating Income Excluding Non-GAAP Adjustments to Operating Income, as measured under GAAP For the Year Ended December 31, 2003 (In millions) Non-GAAP GAAP Adjustments Adjusted Specialty Pharmaceutica
Table 6 Valeant Pharmaceuticals International Reconciliation of Specialty Pharmaceuticals Adjusted Operating Income Excluding Non-GAAP Adjustments to Operating Income, as measured under GAAP For the Year Ended December 31, 2002 (In millions) Non-GAAP GAAP Adjustments Adjusted Specialty Pharmaceutica
Slide 8: Table 7: EBITDA Reconciliation, 2004
Table 7 Valeant Pharmaceuticals International Reconciliation of EBITDA Excluding Non-GAAP Adjustments to EBITDA, as measured under GAAP For the Year Ended December 31, 2004 (In millions) Non-GAAP GAAP Adjustments Adjusted Specialty pharmaceuticals Adjusted operating income (from Table 4) $ 50 $ 29(a
Slide 9: Table 8: EBITDA Reconciliation, 2003
Table 8 Valeant Pharmaceuticals International Reconciliation of EBITDA Excluding Non-GAAP Adjustments to EBITDA, as measured under GAAP For the Year Ended December 31, 2003 (In millions) Non-GAAP GAAP Adjustments Adjusted Specialty pharmaceuticals Adjusted operating income (from Table 5) $ 43 $ — $
Slide 10: Table 9: EBITDA Reconciliation, 2002
Table 9 Valeant Pharmaceuticals International Reconciliation of EBITDA Excluding Non-GAAP Adjustments to EBITDA, as measured under GAAP For the Year Ended December 31, 2002 (In millions) Non-GAAP GAAP Adjustments Adjusted Specialty pharmaceuticals Adjusted operating income (loss) (from Table 6) $ (2
Source: SEC EDGAR · 8-K filed Nov 30, 2005
More decks from Valeant Pharmaceuticals International Inc